Dashboard
1
With a growth in Net Sales of 25.38%, the company declared Very Positive results in Sep 25
- The company has declared positive results for the last 2 consecutive quarters
- ROCE(HY) Highest at 6.86%
- INTEREST COVERAGE RATIO(Q) Highest at 1,289.5
- RAW MATERIAL COST(Y) Fallen by -2.66% (YoY)
2
Market Beating performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 7,820 Million (Mid Cap)
173.00
NA
0.00%
0.18
6.56%
8.15
Revenue and Profits:
Net Sales:
197 Million
(Quarterly Results - Dec 2025)
Net Profit:
-25 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
19.79%
0%
19.79%
6 Months
11.69%
0%
11.69%
1 Year
99.21%
0%
99.21%
2 Years
234.95%
0%
234.95%
3 Years
40.0%
0%
40.0%
4 Years
36.79%
0%
36.79%
5 Years
0%
0%
0.0%
Chengdu Olymvax Biopharmaceuticals, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
17.39%
EBIT Growth (5y)
-4.86%
EBIT to Interest (avg)
15.30
Debt to EBITDA (avg)
0.61
Net Debt to Equity (avg)
0.18
Sales to Capital Employed (avg)
0.46
Tax Ratio
15.47%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.29%
ROE (avg)
4.40%
Valuation key factors
Factor
Value
P/E Ratio
173
Industry P/E
Price to Book Value
11.18
EV to EBIT
162.83
EV to EBITDA
101.91
EV to Capital Employed
9.46
EV to Sales
15.88
PEG Ratio
0.75
Dividend Yield
NA
ROCE (Latest)
5.81%
ROE (Latest)
6.45%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
197.20
202.20
-2.47%
Operating Profit (PBDIT) excl Other Income
-13.20
24.80
-153.23%
Interest
3.80
3.90
-2.56%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-25.20
15.80
-259.49%
Operating Profit Margin (Excl OI)
-124.70%
77.40%
-20.21%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is -2.47% vs 40.61% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is -259.49% vs 208.22% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
701.50
587.40
19.42%
Operating Profit (PBDIT) excl Other Income
76.00
57.40
32.40%
Interest
15.10
14.50
4.14%
Exceptional Items
0.00
0.00
Consolidate Net Profit
21.90
15.70
39.49%
Operating Profit Margin (Excl OI)
46.90%
36.50%
1.04%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 19.42% vs 18.83% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 39.49% vs 37.72% in Dec 2024
About Chengdu Olymvax Biopharmaceuticals, Inc. 
Chengdu Olymvax Biopharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






